Programmed death-ligand 1 (PD-L1) is an immune-related biomarker that can be expressed on the surface of many tissue types, including tumor cells. For certain types and stages of cancer, testing for PD-L1 expression may aid in prediction of response to treatment with PD-L1 inhibitors such as atezolizumab (TECENTRIQ), durvalumab (IMFINZI), nivolumab (OPDIVO), and pembrolizumab (KEYTRUDA). Selection of the appropriate test depends on the malignancy and the drug being considered.

Refer to ARUP Laboratories’ test offerings below.